A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT)
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Maribavir (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Takeda
- 24 Jun 2024 According to Takeda media release, company announced that LIVTENCITY (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies on basis of NCT02931539 and NCT05137717 trial.
- 30 Jun 2023 Status changed from active, no longer recruiting to completed.
- 01 Mar 2023 Status changed from recruiting to active, no longer recruiting.